Tags : Tremfya (guselkumab)

Clinical Trials

Johnson & Johnson Report Long-Term Data of Tremfya (guselkumab) in

Shots: The P-III DISCOVER-2a study involves assessing Tremfya (q4w/ q8w, SC) in bio-naïve patients with active PsA Results: @100wks. complete skin clearance (PASI 100) (59 %/53%); improvement in joint symptoms (ACR 20) (76%/74%). The findings confirmed that the robust efficacy of Tremfya demonstrated in patients @24wks. on physical function, physical aspects of health-related QoL, and […]Read More